(Q30689186)

English

Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

chronic hepatitis B

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

author name string

Steven Crowley

1

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

David Tognarini

2

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Paul Desmond

3

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Michael Lees

4

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Gauri Saal

5

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

publication date

1 February 2002

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Journal of Gastroenterology and Hepatology

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

153-164

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Epidemiology of hepatitis B infection in the Western Pacific and South East Asia

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02673.X

21 January 2018

Natural history of chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02673.X

21 January 2018

Therapy of viral hepatitis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02673.X

21 January 2018

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02673.X

21 January 2018

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02673.X

21 January 2018

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02673.X

21 January 2018

The Assessment of Quality of Life (AQoL) instrument: a psychometric measure of health-related quality of life

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02673.X

21 January 2018

The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep).

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02673.X

21 January 2018

The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02673.X

21 January 2018

Long-term effect of interferon therapy in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02673.X

21 January 2018

The development of cirrhosis in patients with chronic type B hepatitis: A prospective study

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02673.X

21 January 2018

Natural history and prognostic factors for chronic hepatitis type B

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02673.X

21 January 2018

Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02673.X

21 January 2018

Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02673.X

21 January 2018

Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02673.X

21 January 2018

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02673.X

21 January 2018

Identifiers

10.1046/J.1440-1746.2002.02673.X

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30689186&oldid=1968046525"